# Our oncology pipeline[1,2]

We are advancing a diversified portfolio of product candidates with transformative **potential to address cancer care across indications with high incidence** …

## Phase 1

- **BNT116** Adv. NSCLC
- **BNT211** Multiple solid tumors
- **BNT314/GEN1059**[9] Multiple solid tumors
- **Beruzatatug pelitecan**[8] Multiple solid tumors

## Phase 1/2

- **BNT317** Multiple solid tumors
- **BNT3214** Multiple solid tumors
- **Elfetabart drozuntecan**[5] Multiple solid tumors
- **Sacituzumab drozuntecan**[5] Multiple solid tumors
- **BNT329** Multiple solid tumors
- **Gotistobart**[7] Met. CRPC
- **Gotistobart**[7] Multiple solid tumors
- **Pumitamig**[3] 1L adv. HCC
- **Pumitamig**[3] Adv. RCC
- **Pumitamig**[3] Multiple solid tumors[11]
- **Pumitamig**[3] 1L adv./met. TNBC[11]
- **Pumitamig**[3] + **BNT314/GEN1059**[9] Met. CRC[4]
- **Pumitamig**[3] + **BNT3212** Multiple solid tumors
- **Pumitamig**[3] + **BNT3213** 1L HCC[4,11]
- **Pumitamig**[3] + **Elfetabart drozuntecan**[5] Adv./met. NSCLC and SCLC[4]
- **Pumitamig**[3] + **Sacituzumab drozuntecan**[5] Multiple solid tumors[4]
- **Pumitamig**[3] + **Beruzatatug pelitecan**[8] Multiple solid tumors
- **Pumitamig**[3] + **Beruzatatug pelitecan**[8] Adv. NSCLC
- **Pumitamig**[3] + **Trastuzumab pamirtecan**[5] Adv./met. BC[4]
- **Trastuzumab pamirtecan**[5] Multiple solid tumors

## Phase 2

- **Autogene cevumeran**[6] Adj. PDAC
- **BNT116**[10] 1L adv. NSCLC
- **Beruzatatug pelitecan**[8] Multiple solid tumors[11]
- **Beruzatatug pelitecan**[8] Adv./met. BC[11]
- **Gotistobart**[7] PROC
- **Pumitamig**[3] 1L met. CRC[11]
- **Pumitamig**[3] 1L ES-SCLC[11]
- **Pumitamig**[3] 1L/2L+ ES-SCLC
- **Pumitamig**[3] 2L ES-SCLC[11]
- **Pumitamig**[3] 2L+ EGFRm NSCLC[11]
- **Pumitamig**[3] 2L Glioblastoma[11]
- **Pumitamig**[3] 2L NEN[11]
- **Pumitamig**[3] 2L adv./met. NSCLC
- **Pumitamig**[3] 1L met. PDAC
- **Pumitamig**[3] 1L/2L adv./met. TNBC
- **Pumitamig**[3] or **Sacituzumab drozuntecan**[5] + **BNT324/DB-1311**[5] Multiple solid tumors[4]

## Phase 2/3

- **Tenumomeran/ Raplemomeran** 1L HPV16+ HNSCC
- **Pumitamig**[3] 1L met. CRC
- **Pumitamig**[3] 1L adv./met. Gastric
- **Pumitamig**[3] 1L NSCLC

## Phase 3

- **Elfetabart drozuntecan**[5] 1L met. CRPC
- **Gotistobart**[7] 2L+ sqNSCLC
- **Pumitamig**[3] 1L ES-SCLC
- **Pumitamig**[3] 1L adv. NSCLC
- **Pumitamig**[3] Unresectable Stage III NSCLC
- **Pumitamig**[3] 2L SCLC[11]
- **Pumitamig**[3] 1L TNBC[12]
- **Pumitamig**[3] 1L adv./met. TNBC[11]
- **Trastuzumab pamirtecan**[5] Met. BC
- **Trastuzumab pamirtecan**[5] 2L EC

mRNA cancer immunotherapy | Targeted therapy | Next generation immunomodulator | Novel-novel combination

1 More details on BioNTech's rights can be found in the Annual Report 2025; 2 BC = Breast cancer; CRC = Colorectal cancer; CRPC = Castration-resistant prostate cancer; EC = Endometrial cancer; EGFRm NSCLC = EGFR-mutant non-small cell lung cancer; ES-SCLC = Extensive-stage small cell lung cancer; HCC = Hepatocellular carcinoma; HNSCC = Head and neck squamous cell carcinoma; NEN = Neuroendocrine neoplasm; NSCLC = Non-small cell lung cancer; PDAC = Pancreatic ductal adenocarcinoma; PROC = Platinum-resistant ovarian cancer; SCLC = Small cell lung cancer; sqNSCLC = squamous non-small cell lung cancer; TNBC = Triple negative breast cancer; 3 Partnered with Bristol Myers Squibb; 4 Trial is currently being conducted by or on behalf of BioNTech. Bristol Myers Squibb holds co-exclusive rights to pumitamig; 5 Partnered with DualityBio; 6 Partnered with Genentech, a member of the Roche Group; 7 Partnered with OncoC4; 8 Partnered with MediLink Therapeutics; 9 Partnered with Genmab; 10 In collaboration with Regeneron; 11 Trial ongoing in China only; 12 Phase 3 collaboration with Gilead; Status: November 2026

# Our infectious disease pipeline[1]

… as well as for **potential prevention or treatment of infectious diseases**.




13 Partnered with University of Pennsylvania; 14 Funded by the Gates Foundation; 15 Funded by the Coalition for Epidemic Preparedness Innovations (CEPI); 16 Partnered with Pfizer; 17 Partnered with Fosun Pharma; Status: November 2026